<i>In vitro</i> Production and Immunogenicity of a <i>Clostridium Difficile</i> Spore-Specific BclA3 Glycopeptide Conjugate Vaccine

<b>A</b><b>bstract: </b>The BclA3 glycoprotein is a major component of the exosporangial layer of <i>Clostridium difficile</i> spores and in this study we demonstrate that this glycoprotein is a major spore surface associated antigen. Here, we confirm the role of...

Full description

Bibliographic Details
Main Authors: Annie Aubry, Wei Zou, Evguenii Vinogradov, Dean Williams, Wangxue Chen, Greg Harris, Hongyan Zhou, Melissa J. Schur, Michel Gilbert, Gillian R. Douce, Susan M. Logan
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:Vaccines
Subjects:
Online Access:https://www.mdpi.com/2076-393X/8/1/73
id doaj-1c1b0413725e462bbe605af367d105fa
record_format Article
spelling doaj-1c1b0413725e462bbe605af367d105fa2020-11-25T01:27:38ZengMDPI AGVaccines2076-393X2020-02-01817310.3390/vaccines8010073vaccines8010073<i>In vitro</i> Production and Immunogenicity of a <i>Clostridium Difficile</i> Spore-Specific BclA3 Glycopeptide Conjugate VaccineAnnie Aubry0Wei Zou1Evguenii Vinogradov2Dean Williams3Wangxue Chen4Greg Harris5Hongyan Zhou6Melissa J. Schur7Michel Gilbert8Gillian R. Douce9Susan M. Logan10Vaccine Program, Human Health Therapeutics Research Centre, National Research Council of Canada, Ottawa K1A 0R6 ON, CanadaVaccine Program, Human Health Therapeutics Research Centre, National Research Council of Canada, Ottawa K1A 0R6 ON, CanadaVaccine Program, Human Health Therapeutics Research Centre, National Research Council of Canada, Ottawa K1A 0R6 ON, CanadaVaccine Program, Human Health Therapeutics Research Centre, National Research Council of Canada, Ottawa K1A 0R6 ON, CanadaVaccine Program, Human Health Therapeutics Research Centre, National Research Council of Canada, Ottawa K1A 0R6 ON, CanadaVaccine Program, Human Health Therapeutics Research Centre, National Research Council of Canada, Ottawa K1A 0R6 ON, CanadaVaccine Program, Human Health Therapeutics Research Centre, National Research Council of Canada, Ottawa K1A 0R6 ON, CanadaVaccine Program, Human Health Therapeutics Research Centre, National Research Council of Canada, Ottawa K1A 0R6 ON, CanadaVaccine Program, Human Health Therapeutics Research Centre, National Research Council of Canada, Ottawa K1A 0R6 ON, CanadaInstitute of Infection, Immunity, Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Scotland G12 8TA, UKVaccine Program, Human Health Therapeutics Research Centre, National Research Council of Canada, Ottawa K1A 0R6 ON, Canada<b>A</b><b>bstract: </b>The BclA3 glycoprotein is a major component of the exosporangial layer of <i>Clostridium difficile</i> spores and in this study we demonstrate that this glycoprotein is a major spore surface associated antigen. Here, we confirm the role of SgtA glycosyltransferase (SgtA GT) in BclA3 glycosylation and recapitulate this process by expressing and purifying SgtA GT fused to MalE, the maltose binding protein from <i>Escherichia coli</i>. In vitro assays using the recombinant enzyme and BclA3 synthetic peptides demonstrated that SgtA GT was responsible for the addition of &#946;-<i>O</i>-linked GlcNAc to threonine residues of each synthetic peptide. These peptide sequences were selected from the central, collagen repeat region of the BclA3 protein. Following optimization of SgtA GT activity, we generated sufficient glycopeptide (10 mg) to allow conjugation to KLH (keyhole limpet hemocyanin) protein. Glycosylated and unglycosylated versions of these conjugates were then used as antigens to immunize rabbits and mice. Immune responses to each of the conjugates were examined by Enzyme Linked Immunosorbent Assay ELISA. Additionally, the BclA3 conjugated peptide and glycopeptide were used as antigens in an ELISA assay with serum raised against formalin-killed spores. Only the glycopeptide was recognized by anti-spore polyclonal immune serum demonstrating that the glycan moiety is a predominant spore-associated surface antigen. To determine whether antibodies to these peptides could modify persistence of spores within the gut, animals immunized intranasally with either the KLH-glycopeptide or KLH-peptide conjugate in the presence of cholera toxin, were challenged with R20291 spores. Although specific antibodies were raised to both antigens, immunization did not provide any protection against acute or recurrent disease.https://www.mdpi.com/2076-393X/8/1/73<i>c. difficile</i> vaccinebcla3 spore glycoproteino-glcnac transferaseglycopeptideconjugateimmunogenicity
collection DOAJ
language English
format Article
sources DOAJ
author Annie Aubry
Wei Zou
Evguenii Vinogradov
Dean Williams
Wangxue Chen
Greg Harris
Hongyan Zhou
Melissa J. Schur
Michel Gilbert
Gillian R. Douce
Susan M. Logan
spellingShingle Annie Aubry
Wei Zou
Evguenii Vinogradov
Dean Williams
Wangxue Chen
Greg Harris
Hongyan Zhou
Melissa J. Schur
Michel Gilbert
Gillian R. Douce
Susan M. Logan
<i>In vitro</i> Production and Immunogenicity of a <i>Clostridium Difficile</i> Spore-Specific BclA3 Glycopeptide Conjugate Vaccine
Vaccines
<i>c. difficile</i> vaccine
bcla3 spore glycoprotein
o-glcnac transferase
glycopeptide
conjugate
immunogenicity
author_facet Annie Aubry
Wei Zou
Evguenii Vinogradov
Dean Williams
Wangxue Chen
Greg Harris
Hongyan Zhou
Melissa J. Schur
Michel Gilbert
Gillian R. Douce
Susan M. Logan
author_sort Annie Aubry
title <i>In vitro</i> Production and Immunogenicity of a <i>Clostridium Difficile</i> Spore-Specific BclA3 Glycopeptide Conjugate Vaccine
title_short <i>In vitro</i> Production and Immunogenicity of a <i>Clostridium Difficile</i> Spore-Specific BclA3 Glycopeptide Conjugate Vaccine
title_full <i>In vitro</i> Production and Immunogenicity of a <i>Clostridium Difficile</i> Spore-Specific BclA3 Glycopeptide Conjugate Vaccine
title_fullStr <i>In vitro</i> Production and Immunogenicity of a <i>Clostridium Difficile</i> Spore-Specific BclA3 Glycopeptide Conjugate Vaccine
title_full_unstemmed <i>In vitro</i> Production and Immunogenicity of a <i>Clostridium Difficile</i> Spore-Specific BclA3 Glycopeptide Conjugate Vaccine
title_sort <i>in vitro</i> production and immunogenicity of a <i>clostridium difficile</i> spore-specific bcla3 glycopeptide conjugate vaccine
publisher MDPI AG
series Vaccines
issn 2076-393X
publishDate 2020-02-01
description <b>A</b><b>bstract: </b>The BclA3 glycoprotein is a major component of the exosporangial layer of <i>Clostridium difficile</i> spores and in this study we demonstrate that this glycoprotein is a major spore surface associated antigen. Here, we confirm the role of SgtA glycosyltransferase (SgtA GT) in BclA3 glycosylation and recapitulate this process by expressing and purifying SgtA GT fused to MalE, the maltose binding protein from <i>Escherichia coli</i>. In vitro assays using the recombinant enzyme and BclA3 synthetic peptides demonstrated that SgtA GT was responsible for the addition of &#946;-<i>O</i>-linked GlcNAc to threonine residues of each synthetic peptide. These peptide sequences were selected from the central, collagen repeat region of the BclA3 protein. Following optimization of SgtA GT activity, we generated sufficient glycopeptide (10 mg) to allow conjugation to KLH (keyhole limpet hemocyanin) protein. Glycosylated and unglycosylated versions of these conjugates were then used as antigens to immunize rabbits and mice. Immune responses to each of the conjugates were examined by Enzyme Linked Immunosorbent Assay ELISA. Additionally, the BclA3 conjugated peptide and glycopeptide were used as antigens in an ELISA assay with serum raised against formalin-killed spores. Only the glycopeptide was recognized by anti-spore polyclonal immune serum demonstrating that the glycan moiety is a predominant spore-associated surface antigen. To determine whether antibodies to these peptides could modify persistence of spores within the gut, animals immunized intranasally with either the KLH-glycopeptide or KLH-peptide conjugate in the presence of cholera toxin, were challenged with R20291 spores. Although specific antibodies were raised to both antigens, immunization did not provide any protection against acute or recurrent disease.
topic <i>c. difficile</i> vaccine
bcla3 spore glycoprotein
o-glcnac transferase
glycopeptide
conjugate
immunogenicity
url https://www.mdpi.com/2076-393X/8/1/73
work_keys_str_mv AT annieaubry iinvitroiproductionandimmunogenicityofaiclostridiumdifficileisporespecificbcla3glycopeptideconjugatevaccine
AT weizou iinvitroiproductionandimmunogenicityofaiclostridiumdifficileisporespecificbcla3glycopeptideconjugatevaccine
AT evgueniivinogradov iinvitroiproductionandimmunogenicityofaiclostridiumdifficileisporespecificbcla3glycopeptideconjugatevaccine
AT deanwilliams iinvitroiproductionandimmunogenicityofaiclostridiumdifficileisporespecificbcla3glycopeptideconjugatevaccine
AT wangxuechen iinvitroiproductionandimmunogenicityofaiclostridiumdifficileisporespecificbcla3glycopeptideconjugatevaccine
AT gregharris iinvitroiproductionandimmunogenicityofaiclostridiumdifficileisporespecificbcla3glycopeptideconjugatevaccine
AT hongyanzhou iinvitroiproductionandimmunogenicityofaiclostridiumdifficileisporespecificbcla3glycopeptideconjugatevaccine
AT melissajschur iinvitroiproductionandimmunogenicityofaiclostridiumdifficileisporespecificbcla3glycopeptideconjugatevaccine
AT michelgilbert iinvitroiproductionandimmunogenicityofaiclostridiumdifficileisporespecificbcla3glycopeptideconjugatevaccine
AT gillianrdouce iinvitroiproductionandimmunogenicityofaiclostridiumdifficileisporespecificbcla3glycopeptideconjugatevaccine
AT susanmlogan iinvitroiproductionandimmunogenicityofaiclostridiumdifficileisporespecificbcla3glycopeptideconjugatevaccine
_version_ 1725104105680011264